Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 360

Results For "ENT"

9427 News Found

Botanic Healthcare launches Rs. 25 crore liposomal manufacturing facility in Hyderabad
Healthcare | September 10, 2025

Botanic Healthcare launches Rs. 25 crore liposomal manufacturing facility in Hyderabad

New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production


Navin Fluorine inaugurates Phase-1 of new cGMP-4 facility of Navin Molecular at Devas
News | September 10, 2025

Navin Fluorine inaugurates Phase-1 of new cGMP-4 facility of Navin Molecular at Devas

The cGMP-4 facility will further strengthen the company's ability to serve global partners


Congruence gets $32 million financing to advance genetic obesity candidate drug
News | September 09, 2025

Congruence gets $32 million financing to advance genetic obesity candidate drug

CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity


FDA grants Fast Track Designation for Teva’s Emrusolmin
Drug Approval | September 09, 2025

FDA grants Fast Track Designation for Teva’s Emrusolmin

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development


SPL Infusion commences commercial production of new IV fluid Infusion plant
News | September 09, 2025

SPL Infusion commences commercial production of new IV fluid Infusion plant

The facility has been designed with a dual focus on efficiency and sustainability


Alcon India launches Unity VCS/CS for vitreoretinal and cataract surgery
News | September 09, 2025

Alcon India launches Unity VCS/CS for vitreoretinal and cataract surgery

Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye


Biocytogen and Merck to advance antibody-conjugated lipid-based delivery solutions
News | September 09, 2025

Biocytogen and Merck to advance antibody-conjugated lipid-based delivery solutions

Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services


MRM Health raises €55 million Series B to advance microbiome-based biotherapeutic product pipeline
News | September 09, 2025

MRM Health raises €55 million Series B to advance microbiome-based biotherapeutic product pipeline

Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval